Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 2
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Caminati, Marco Dama, Anna Rita Djuric, Ivana Montagni, Marcello Schiappoli, Michele Ridolo, Erminia Senna, Gianenrico and Canonica, Giorgio Walter 2015. Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety. Expert Review of Clinical Immunology, Vol. 11, Issue. 2, p. 233.

    Iglesias-Cadarso, Alfredo and Hernández-Weigand, Pilar 2011. Risk factors for systemic reactions to allergen immunotherapy. Current Opinion in Allergy and Clinical Immunology, Vol. 11, Issue. 6, p. 579.


Safety of sublingual grass pollen immunotherapy after anaphylaxis

  • J R Nichani (a1) and J de Carpentier (a1)
  • DOI:
  • Published online: 01 May 2008

To demonstrate that sublingual immunotherapy is a safe treatment option in patients who have previously suffered anaphylaxis when undergoing subcutaneous grass pollen immunotherapy.

Case report:

We report two patients who developed a systemic anaphylactic reaction following subcutaneous grass pollen immunotherapy, resulting in discontinuation of treatment. Following treatment of the acute anaphylactic episode, both patients were subsequently safely commenced on sublingual grass pollen immunotherapy.


Injection immunotherapy has a relatively low risk of severe adverse events, although anaphylaxis is a potentially fatal complication and usually results in termination of the immunotherapy programme. Sublingual immunotherapy has a safer side effect profile than subcutaneous immunotherapy, with no reported cases of anaphylaxis.

Corresponding author
Address for correspondence: Mrs J R Nichani, 14 Uplands Chase, Fulwood, Preston PR2 7AW, UK. Fax: 01772 523233 E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1J Bousquet , P van Cauwenberge , N Khaltaev . Allergic rhinitis and its impact on asthma (ARIA). The World Health Organization Initiative. J Allergy Clin Immunol 2001;108(suppl 5):S147–334

2VA Varney , M Gaga , AJ Frew , VR Aber , AB Kay , SR Durham . Usefulness of immunotherapy in subjects with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:265–9

3SM Walker , VA Varney , M Gaga , MR Jacobson , SR Durham . Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995;50:405–13

4I Dolz , C Martinez-Cocera , JM Bartolome , M Cimarra . A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract during a 3 year period with initial rush immunotherapy. Allergy 1996;51:489500

5SR Durham , SM Walker , EM Varga , MR Jacobson , F O'Brien , W Noble Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341:468–75

6RF Lockey , GL Nicoara-Kasti , DS Theodoropoulos , SC Bukantz . Systemic reactions and fatalities associated with allergen immunotherapy. Ann Allergy Asthma Immunol 2001;87(suppl 1):4755

7DG Tinkleman , WQ Cole , J Tunno . Immunotherapy: a one year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 1995;95:814

8PA Ostergaard , PH Kaad , T Kristensen . A prospective study on the safety of immunotherapy in children with severe asthma. Allergy 1986;41:567–78

9V Bauchau , SR Durham . Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758–64

11Committee on safety of medicines. Desensitising vaccines. BMJ 1986;293:948

12DR Wilson , LI Torres , SR Durham . Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003;(2):CD002893

13J Kleine-Tebbe , M Ribel , DA Herold . Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006:61:181–4

14R Dahl , A Kapp , G Colombo , J de Monchy , S Rak , W Emminger Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434–40

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The Journal of Laryngology & Otology
  • ISSN: 0022-2151
  • EISSN: 1748-5460
  • URL: /core/journals/journal-of-laryngology-and-otology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *